Phase 3Not yet recruiting

Semaglutide in Alcohol Use Disorder

A 45-week, Randomized, Controlled Trial of Semaglutide on Alcohol Related Outcomes in Adults With Alcohol Use Disorder and Obesity

Sponsor
University of Minnesota (Academic or other)
Enrollment
128 planned
Conditions
Alcohol Use Disorder (AUD); Obesity
Interventions
Wegovy; Placebo
Ages
adults, older adults
Registry
NCT07949474

Full record on ClinicalTrials.gov

From the registry

This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.

Primary outcomes

  • Heavy drinking days
  • Total drinking days

History

  1. Study completion expected

  2. Primary completion expected

  3. Expected to start

  4. Registered